Zyprexa Willful Infringement Claim Dismissal Could Speed Ivax Launch
Executive Summary
Ivax said it is more likely to launch its generic of the antipsychotic Zyprexa ahead of an appellate court decision now that Lilly has agreed to dismiss a willful infringement claim prior to trial
You may also be interested in...
Lilly Elevates Santini To Senior VP; “Access & Policy” Are Priorities
Lilly is placing additional emphasis on prescription drug access and pricing issues with the appointment of U.S. Operations President Gino Santini to senior VP-corporate strategy and policy
Lilly Elevates Santini To Senior VP; “Access & Policy” Are Priorities
Lilly is placing additional emphasis on prescription drug access and pricing issues with the appointment of U.S. Operations President Gino Santini to senior VP-corporate strategy and policy
Ivax Zyprexa Patent Challenge Could Benefit From Paxil Invalidity Ruling
Ivax believes its challenge to Lilly's Zyprexa patent will get a boost from a recent appellate court decision invalidating a GlaxoSmithKline patent claim for Paxil